Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Alevaire
2. Enuclene
3. Formaldehyde, Polymer With Oxirane And 4-(1,1,3,3-tetramethylbutyl)phenol
4. Oxyethylated Tertiary Octylphenol Formaldehyde Polymer
5. P-isooctylpolyoxyethylenephenol Formaldehyde Polymer
6. Polyhydroxyethyl-tert-octylphenolformaldehyde
7. Superinone
8. Supervent
9. Translight
10. Triton A 20
11. Triton Wr 1339
12. Triton Wr-1339
13. Tyloxapol
14. Tyroxapol
15. Wr-1339
1. Tyloxapol
2. 25301-02-4
3. Tyloxypal
4. Triton Wr-1339
5. Superinone
6. Alevaire
7. Nsc90255
8. Formaldehyde;oxirane;4-(2,4,4-trimethylpentan-2-yl)phenol
9. Triton A-20
10. Formaldehyde, Polymer With Oxirane And4-(1,1,3,3-tetramethylbutyl)phenolother Ca Index Names:oxirane, Polymer With Formaldehyde And4-(1,1,3,3-tetramethylbutyl)phenolphenol, 4-(1,1,3,3-tetramethylbutyl)-, Polymer With Formaldehyde Andoxirane
11. Superiuone
12. Component Of Alevaire
13. Formaldehyde; Oxirane; 4-(1,1,3,3-tetramethylbutyl)phenol
14. Schembl181284
15. Dtxsid30179950
16. Chebi:141517
17. Nsc-90255
18. Akos026749862
19. Formaldehyde,1,3,3-tetra Methylbutyl)phenol
20. Ab01563398_01
21. Q7860340
22. Ethoxylated P-tert-octylphenol Formaldehyde Polymer
23. Wln: /qr Dx1&1&1x1&1&1/ &/*o2*/ &/*o1*/
24. Phenol,1,3,3-tetramethylbutyl)-, Polymer With Ethylene Oxide And Formaldehyde
| Molecular Weight | 280.4 g/mol |
|---|---|
| Molecular Formula | C17H28O3 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 3 |
| Exact Mass | 280.20384475 g/mol |
| Monoisotopic Mass | 280.20384475 g/mol |
| Topological Polar Surface Area | 49.8 Ų |
| Heavy Atom Count | 20 |
| Formal Charge | 0 |
| Complexity | 204 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 3 |
Tyloxapol is an inhaled surfactant that assists in removing and liquefying and removing bronchopulmonary secretions with mucus and pus. Tyloxapol is administered either through nebulized solution or a stream of oxygen. Also investigated for use/treatment in cystic fibrosis and pediatric indications.
It is used as a surfactant to aid liquefaction and removal of mucopurulent (containing mucus and pus) bronchopulmonary secretions. Tyloxapol also blocks plasma lipolytic activity, and thus the breakdown of triglyceride-rich lipoproteins.
Surface-Active Agents
Agents that modify interfacial tension of water; usually substances that have one lipophilic and one hydrophilic group in the molecule; includes soaps, detergents, emulsifiers, dispersing and wetting agents, and several groups of antiseptics. (See all compounds classified as Surface-Active Agents.)
Detergents
Purifying or cleansing agents, usually salts of long-chain aliphatic bases or acids, that exert cleansing (oil-dissolving) and antimicrobial effects through a surface action that depends on possessing both hydrophilic and hydrophobic properties. (See all compounds classified as Detergents.)
R - Respiratory system
R05 - Cough and cold preparations
R05C - Expectorants, excl. combinations with cough suppressants
R05CA - Expectorants
R05CA01 - Tyloxapol
Tyloxapol, when injected IP, blocks plasma lipolytic activity, and thus the breakdown of triglyceride-rich lipoproteins. It has also been shown to be inhibitor of lipoprotein lipase, thus preventing triglyceride uptake.
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Tyloxapol API manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Tyloxapol API, including repackagers and relabelers. The FDA regulates Tyloxapol API manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Tyloxapol API API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Tyloxapol API supplier is an individual or a company that provides Tyloxapol API active pharmaceutical ingredient (API) or Tyloxapol API finished formulations upon request. The Tyloxapol API suppliers may include Tyloxapol API API manufacturers, exporters, distributors and traders.
Tyloxapol API Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Tyloxapol API GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Tyloxapol API GMP manufacturer or Tyloxapol API GMP API supplier for your needs.
A Tyloxapol API CoA (Certificate of Analysis) is a formal document that attests to Tyloxapol API's compliance with Tyloxapol API specifications and serves as a tool for batch-level quality control.
Tyloxapol API CoA mostly includes findings from lab analyses of a specific batch. For each Tyloxapol API CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Tyloxapol API may be tested according to a variety of international standards, such as European Pharmacopoeia (Tyloxapol API EP), Tyloxapol API JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Tyloxapol API USP).
LOOKING FOR A SUPPLIER?
